Xifaxan is a brand name for the antibiotic rifaximin. It is used primarily to reduce the risk of hepatic encephalopathy in patients with advanced liver disease. The drug is also approved for the treatment of travel-associated diarrhea caused by certain bacteria. Its active ingredient rifaximin works by modulating the gut microbiota without being absorbed systemically. By limiting the growth of ammonia-producing bacteria in the intestine, it lowers the levels of toxic metabolites that can impair brain function. This reduction in ammonia and other harmful substances helps maintain normal neurological signaling in the brain. Consequently patients experience fewer episodes of hepatic encephalopathy and improved quality of life. The medication therefore serves as a targeted therapy that acts locally in the gastrointestinal tract to support liver function.

Xifaxan is a minimally absorbed antibiotic marketed for travel-associated diarrhea caused by specific strains of escherichia coli. Its active ingredient, rifaximin, remains largely in the gut because it is poorly absorbed systemically. Pharmacologically, rifaximin inhibits bacterial rna polymerase, disrupting transcription and impairing microbial replication. This selective inhibition reduces the growth of pathogenic bacteria without substantially affecting the normal intestinal microbiota. Therapeutically, Xifaxan is used to treat non-invasive travelers diarrhea and to reduce the risk of recurrent hepatic encephalopathy in adults with liver disease. By eliminating toxin-producing organisms, it alleviates diarrhea symptoms and prevents further intestinal damage. The medication localized action preserves gut flora balance while providing targeted antimicrobial effect.

Xifaxan may cause nausea and abdominal discomfort in some patients. Headache and dizziness are also reported side effects. Bloating and excess gas are common gastrointestinal symptoms. Fatigue and mild liver enzyme elevations can occur occasionally. These effects are generally mild and often resolve without intervention. Patients may experience a metallic taste or changes in taste sensation. Overall the medication is considered safe when used as prescribed.

Headache and dizziness are frequently reported as common side effects of Xifaxan. Nausea and mild abdominal discomfort may also occur during treatment. Fatigue and occasional flatulence are additional symptoms some patients experience. These reactions are generally mild and often resolve without specific treatment. The incidence of severe adverse effects is low and not typically observed in clinical reports. Overall the medication is well tolerated by most users with only these modest symptoms.